

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Breen Michael Martin (Last) (First) (Middle) C/O GT BIOPHARMA, INC., 9350 WILSHIRE BLVD., STE. 203 (Street) BEVERLY HILLS, CA 90212 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/13/2021	3. Issuer Name and Ticker or Trading Symbol GT Biopharma, Inc. [GTBP]		
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		5. If Amendment, Date Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
10% Senior Convertible Debenture	09/07/2018	(1)	Common Stock	(1)	\$ 3.4 (1)	D	
10% Senior Convertible Debenture	06/23/2020	06/23/2021	Common Stock	(2)	\$ 3.4 (2)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Breen Michael Martin C/O GT BIOPHARMA, INC. 9350 WILSHIRE BLVD., STE. 203 BEVERLY HILLS, CA 90212	X			

Signatures

/s/ Michael Martin Bree	11/09/2021
<small>*Signature of Reporting Person</small>	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Reflects a 10% Senior Convertible Debenture in the face amount of \$100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay
- (1) the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of \$3.40 (which reflects the applicable conversion price on a post-reverse split basis).
 - (2) Reflects a 10% Senior Convertible Debenture in the face amount of \$30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of \$3.40 (which reflects the applicable conversion price on a post-reverse split basis)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.